Here's Why Quest Diagnostics (DGX) is a Strong Value Stock

Quest Diagnostics (DGX) is identified as a strong value stock, rated a #3 (Hold) by Zacks, with B-rated Value and VGM Style Scores. The diagnostic services provider exhibits attractive valuation, evidenced by a 18.42 forward P/E. Upward revisions by two analysts lifted the FY2025 consensus earnings estimate to $9.70/share, alongside a 2% average earnings surprise, positioning DGX as a potential short-list candidate for investors.

Analysis

Quest Diagnostics (DGX) presents a mixed but compelling profile for value-focused investors, according to Zacks' proprietary rating system. While the stock holds a neutral Zacks Rank of #3 (Hold), indicating expected performance in line with the market, its underlying metrics suggest strength in valuation. The company scores a 'B' for both its overall VGM (Value, Growth, Momentum) Score and its specific Value Style Score, supported by an attractive forward P/E ratio of 18.42. The earnings outlook shows modest positive momentum, with the fiscal 2025 consensus earnings estimate rising by $0.01 to $9.70 per share based on two upward revisions in the last 60 days. This is further complemented by a historical average earnings surprise of 2%, suggesting consistent operational execution. The analysis positions DGX's appeal on its valuation characteristics rather than on expectations of significant near-term outperformance.

Key Decisions for Investors

• Value-oriented investors may find the current valuation attractive, supported by a 'B' Value Score and a forward P/E of 18.42, justifying consideration for a position.
• Given the neutral #3 (Hold) rank, investors holding DGX might maintain their positions, as the rating suggests no immediate sell signals but also no strong catalyst for near-term outperformance.
• Investors should monitor for further upward earnings estimate revisions, as a change in the Zacks Rank from #3 (Hold) to #2 (Buy) could signal an improving fundamental outlook and act as a bullish trigger.